Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 12 · newest first

  1. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic LeukemiaJAMA Oncology · 2017
  2. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017Journal of the National Comprehensive Cancer Network · 2017
  3. Clinical outcomes in adult patients with aplastic anemia: A single institution experienceAmerican Journal of Hematology · 2017
  4. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignanciesCancer · 2017
  5. Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatmentBlood · 2017
  6. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study resultsBlood · 2017
  7. Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML groupBlood Advances · 2017
  8. Immunotherapy based approaches in myelofibrosisExpert Review of Hematology · 2017
  9. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicinFuture Oncology · 2017
  10. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNBlood · 2017
  11. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid LeukemiaInternational Journal of Molecular Sciences · 2017
  12. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patientsCancer · 2017
  13. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndromeHaematologica · 2017
  14. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosisBlood Advances · 2017
  15. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2017
  16. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemiaCancer · 2017
  17. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemiaBlood Cancer Journal · 2017
  18. The emerging role of immune checkpoint based approaches in AML and MDSLeukemia & lymphoma/Leukemia and lymphoma · 2017
  19. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid LeukemiaApplied immunohistochemistry & molecular morphology · 2017
  20. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuationBlood · 2017
  21. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemiaHaematologica · 2017
  22. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyBlood Advances · 2017
  23. Copy number alterations detected as clonal hematopoiesis of indeterminate potentialBlood Advances · 2017
  24. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive LeukemiasClinical Lymphoma Myeloma & Leukemia · 2017
  25. A consensus review on malignancy‐associated hemophagocytic lymphohistiocytosis in adultsCancer · 2017
  26. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacyBritish Journal of Haematology · 2017
  27. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemiaBritish Journal of Haematology · 2017
  28. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimensCancer · 2017
  29. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaBlood · 2017
  30. Factors associated with risk of central nervous system relapse in patients with non‐core binding factor acute myeloid leukemiaAmerican Journal of Hematology · 2017
  31. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaAmerican Journal of Hematology · 2017
  32. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approachCancer · 2017
  33. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutationCancer · 2017
  34. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromesAmerican Journal of Hematology · 2017
  35. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agentsAmerican Journal of Hematology · 2017
  36. A phase 1 study of AMG 900, an orally administered pan‐aurora kinase inhibitor, in adult patients with acute myeloid leukemiaAmerican Journal of Hematology · 2017
  37. Acute lymphoblastic leukemia in adolescents and young adultsCancer · 2017
  38. Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphomaAmerican Journal of Hematology · 2017
  39. Myeloid neoplasms with concurrent BCR‐ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasmAmerican Journal of Hematology · 2017
  40. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemiaBlood · 2017
  41. Cancer Drugs: An International Comparison of Postlicensing Price InflationJournal of Oncology Practice · 2017
  42. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialJournal of Hematology & Oncology · 2017
  43. High cancer drug prices 4 years later—Progress and prospectsCancer · 2017
  44. Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinibCancer · 2017
  45. High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in AdultsJournal of Clinical Oncology · 2017
  46. Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromesCancer · 2017
  47. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid LeukemiaClinical Cancer Research · 2017
  48. Validation of a clinical assay of multi‐locus DNA methylation for prognosis of newly diagnosed AMLAmerican Journal of Hematology · 2017
  49. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsAmerican Journal of Hematology · 2017
  50. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United StatesJournal of Clinical Oncology · 2017